{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T02:11:38Z","timestamp":1777774298268,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSTC 113-2124-M-037-001"],"award-info":[{"award-number":["NSTC 113-2124-M-037-001"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["111-2314-B-037-051-MY3"],"award-info":[{"award-number":["111-2314-B-037-051-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["111-2314-B-037-094-MY3"],"award-info":[{"award-number":["111-2314-B-037-094-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["111-2124-M-037-001"],"award-info":[{"award-number":["111-2124-M-037-001"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["110-2320-B-037-010-MY3"],"award-info":[{"award-number":["110-2320-B-037-010-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["112-2320-B-037-011-MY3"],"award-info":[{"award-number":["112-2320-B-037-011-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC114-2823-8-037-001"],"award-info":[{"award-number":["NSTC114-2823-8-037-001"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC113-2314-B-037-064"],"award-info":[{"award-number":["NSTC113-2314-B-037-064"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005057","name":"National Tsing Hua University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004725","name":"Ministry of Economic Affairs","doi-asserted-by":"publisher","award":["112-EC-17-A-17-S6-021"],"award-info":[{"award-number":["112-EC-17-A-17-S6-021"]}],"id":[{"id":"10.13039\/501100004725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMU-TC112A03"],"award-info":[{"award-number":["KMU-TC112A03"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMUH113-3R61"],"award-info":[{"award-number":["KMUH113-3R61"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["NHRPKMU-114-I002"],"award-info":[{"award-number":["NHRPKMU-114-I002"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KT112P002"],"award-info":[{"award-number":["KT112P002"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMU-TC114A03"],"award-info":[{"award-number":["KMU-TC114A03"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMUH114-4R76"],"award-info":[{"award-number":["KMUH114-4R76"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMUH112-2R70"],"award-info":[{"award-number":["KMUH112-2R70"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMU-M114003"],"award-info":[{"award-number":["KMU-M114003"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["112001"],"award-info":[{"award-number":["112001"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["112001-2"],"award-info":[{"award-number":["112001-2"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["114001-2"],"award-info":[{"award-number":["114001-2"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["112002"],"award-info":[{"award-number":["112002"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["115002-2"],"award-info":[{"award-number":["115002-2"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["114001-1"],"award-info":[{"award-number":["114001-1"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["112001-1"],"award-info":[{"award-number":["112001-1"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ijbiomac.2026.151096","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T16:14:01Z","timestamp":1772036041000},"page":"151096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Selective activation of pro-anti-CTLA-4 antibody maintains therapeutic efficacy and reduces immune-related adverse events"],"prefix":"10.1016","volume":"352","author":[{"given":"Bo-Cheng","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Ting","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Yi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Wen","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-min","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Chin","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-An","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"En-Shuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Ching","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pin-Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiao-Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian-Lu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Yii","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Hung","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2026.151096_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2017.00064","article-title":"Advancing cancer therapy with present and emerging immuno-oncology approaches","volume":"7","author":"Kamta","year":"2017","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.151096_bb0010","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1080\/21645515.2015.1129478","article-title":"Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management","volume":"12","author":"Savoia","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"issue":"16","key":"10.1016\/j.ijbiomac.2026.151096_bb0015","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.ijbiomac.2026.151096_bb0020","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2026.151096_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.07.001","article-title":"Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial","volume":"119","author":"Eggermont","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"28","key":"10.1016\/j.ijbiomac.2026.151096_bb0030","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.151096_bb0035","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/CMAR.S31873","article-title":"Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma","volume":"4","author":"Andrews","year":"2012","journal-title":"Cancer Manag. Res."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.151096_bb0040","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2026.151096_bb0045","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.scitotenv.2012.10.092","article-title":"Lower-dose prescribing: minimizing \u201cside effects\u201d of pharmaceuticals on society and the environment","volume":"443","author":"Daughton","year":"2013","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.ijbiomac.2026.151096_bb0050","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.ijbiomac.2026.151096_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.iotech.2024.100713","article-title":"Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy\u2014a retrospective and biomarker study","volume":"22","author":"Costa Svedman","year":"2024","journal-title":"Immuno-Oncology and Technology"},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.151096_bb0060","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1111\/1759-7714.13589","article-title":"Use of glucocorticoids in the management of immunotherapy-related adverse effects","volume":"11","author":"Wang","year":"2020","journal-title":"Thoracic Cancer"},{"issue":"18","key":"10.1016\/j.ijbiomac.2026.151096_bb0065","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151096_bb0070","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000457","article-title":"Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"4","author":"Fuc\u00e0","year":"2019","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151096_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000286","article-title":"Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy","volume":"17","author":"Lu","year":"2019","journal-title":"PLoS Biol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151096_bb0080","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12929-020-00652-z","article-title":"Ab locks for improving the selectivity and safety of antibody drugs","volume":"27","author":"Lin","year":"2020","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151096_bb0085","article-title":"Selective activation of pro-anti-IL-1\u03b2 antibody enhances specificity for autoinflammatory disorder therapy","volume":"11","author":"Lin","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2026.151096_bb0090","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7150\/thno\/v01p0018","article-title":"Real-time video imaging of protease expression in vivo","volume":"1","author":"Zhu","year":"2011","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151096_bb0095","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2249.2009.03933.x","article-title":"Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex","volume":"157","author":"King","year":"2009","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151096_bb0100","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4049\/jimmunol.1302455","article-title":"Humanized mice as a model for aberrant responses in human T cell immunotherapy","volume":"193","author":"Vudattu","year":"2014","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151096_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227470","article-title":"iTRAQ proteomics reveals the regulatory response to Magnaporthe oryzae in durable resistant vs. susceptible rice genotypes","volume":"15","author":"Ma","year":"2020","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.151096_bb0110","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2005-06-2298","article-title":"Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti\u2013CTLA-4 antibodies","volume":"106","author":"Lute","year":"2005","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ijbiomac.2026.151096_bb0115","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1073\/pnas.85.22.8628","article-title":"CD45 regulates signal transduction and lymphocyte activation by specific association with receptor molecules on T or B cells","volume":"85","author":"Ledbetter","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"36","key":"10.1016\/j.ijbiomac.2026.151096_bb0120","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.ijbiomac.2026.151096_bb0125","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.151096_bb0130","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005780","article-title":"FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy","volume":"10","author":"Choueiri","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.151096_bb0135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2017.01.009","article-title":"Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma","volume":"75","author":"Zimmer","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"21","key":"10.1016\/j.ijbiomac.2026.151096_bb0140","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151096_bb0145","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.151096_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21124427","article-title":"Combination of ipilimumab and nivolumab in cancers: from clinical practice to ongoing clinical trials","volume":"21","author":"Kooshkaki","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.151096_bb0155","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in patients with high-risk resectable metastatic melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat. Med."},{"issue":"22","key":"10.1016\/j.ijbiomac.2026.151096_bb0160","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1158\/0008-5472.CAN-21-2483","article-title":"A probody T cell\u2013engaging bispecific antibody targeting EGFR and CD3 inhibits colon cancer growth with limited toxicity","volume":"82","author":"Boustany","year":"2022","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.151096_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.70015","article-title":"Spatial-hindrance-based pro-Adalimumab prevents anti-idiotypic antibody interference in pharmacokinetic and therapeutic efficacy","volume":"10","author":"Huang","year":"2025","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.ijbiomac.2026.151096_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.141003","article-title":"Development of a tumor-region-selective activation monoclonal antibody targeting the 4-1BB receptor for enhanced therapeutic efficacy and safety","volume":"305","author":"Liao","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2026.151096_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.143176","article-title":"Protease-activated anti-Lewis Y antibody enhances selectivity and safety of glycan-targeting cancer therapy","volume":"309","author":"Lee","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"28","key":"10.1016\/j.ijbiomac.2026.151096_bb0180","doi-asserted-by":"crossref","first-page":"9759","DOI":"10.1039\/D1SC01748A","article-title":"Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies","volume":"12","author":"Huang","year":"2021","journal-title":"Chem. Sci."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.151096_bb0185","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-21-3656","article-title":"Praluzatamab ravtansine, a CD166-targeting antibody\u2013drug conjugate, in patients with advanced solid tumors: an open-label phase I\/II trial","volume":"28","author":"Boni","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.151096_bb0190","doi-asserted-by":"crossref","DOI":"10.1002\/pro.5124","article-title":"Integrating molecular dynamics simulation with small- and wide-angle X-ray scattering to unravel the flexibility, antigen-blocking, and protease-restoring functions in a hindrance-based pro-antibody","volume":"33","author":"Liao","year":"2024","journal-title":"Protein Sci."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026010226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026010226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:41:28Z","timestamp":1777484488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026010226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":38,"alternative-id":["S0141813026010226"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.151096","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective activation of pro-anti-CTLA-4 antibody maintains therapeutic efficacy and reduces immune-related adverse events","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.151096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"151096"}}